맞춤형 의료 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Personalized Medicine Market Size, Share & Trends Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics), By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,191,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,568,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,321,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

맞춤형 의료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 맞춤형 의료 시장 규모는 2030년까지 9,098억 달러에 달하며, 2024-2030년의 CAGR은 8.20%로 확대할 것으로 예측됩니다. 이 시장은 질병 발생률 증가와 새로운 치료제에 대한 수요 증가로 인해 2023-2030년 7.20%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예측됩니다. 맞춤형 의료의 새로운 적용은 방대한 연구 노력을 통해 지속적으로 강화되고 있습니다. 예를 들어 2022년 7월 UMass Chan Medical School의 연구진은 개인의 유전체, 식단, 미생물 군집 및 관련 환경 요인과의 연관성을 측정하기 위해 신진대사의 변화를 이해하는 데 도움이 되는 미생물 기반 맞춤형 의료 모델 시스템을 개발했습니다.

대부분의 암은 유전적 불일치로 인해 발생하며, 진행되면 치명적인 증상을 유발합니다. 특정 유전체 특성을 이해하면 암 상태를 효과적이고 정확하게 치료할 수 있습니다. 예를 들어 2020년 5월 키아젠은 QIAseq pan-cancer multi-modal panel을 출시하여 고형암 및 헴스 악성종양 프로파일링을 위한 정밀의료에 폭넓게 적용될 수 있도록 암 환자의 유전체 특성을 안정적으로 분석할 수 있도록 했습니다.

시장은 NGS 기술의 발전과 인간 유전체에 대한 광범위한 조사로 인해 활발하게 움직이고 있습니다. NGS를 활용해 암 및 희귀 유전질환 치료에 사용될 수 있는 맞춤형 의료 결과를 도출하는 데 점점 더 많은 관심이 집중되고 있습니다. 예를 들어 일루미나는 파리에서 열리는 유럽종양학회(ESMO) 연례총회에서 여러 종양학 연구 초록을 발표할 예정이라고 밝혔습니다. 일루미나의 연구는 생검의 종합적인 유전체 프로파일링을 사용하여 피험자를 잠재적인 약물 및 면역 요법에 맞게 조정하여 개인화된 암 치료를 가능하게합니다.

원격의료는 물리적 편의를 돕기 위해 가상 또는 전화로 임상 자문을 용이하게 합니다. 원격의료는 특히 COVID-19 팬데믹 이후 점점 더 많은 추세를 보이고 있습니다. 정부와 연구기관은 개인화 원격의료의 응용을 강화하기 위해 많은 노력을 기울이고 있습니다. 예를 들어 2022년 8월 미국 국립암연구소는 미국 전역에 원격의료 연구센터(Telehealth Research Centers of Excellence: TRACE)의 설립을 지원하기 위해 5년간 2,300만 달러를 지원하겠다고 선언했습니다.

분자영상 시스템과 의료기기는 맞춤형 의료의 새로운 발전에서 중요한 역할을 하고 있습니다. 분자 이미징 시스템과 의료기기는 다양한 유형의 암 치료에서 맞춤형 의료의 응용을 효과적으로 활용하고 있습니다. 예를 들어 2022년 6월 GE헬스케어는 갈륨-68 방사성동위원소를 이용한 전립선암 진단 및 모니터링용 첨단 분자 이미징을 발표했습니다.

이 시장은 새로운 기술 발전과 함께 제휴 및 사업 확장 등 일관된 산업적 노력으로 인해 성장 단계에 있습니다. 예를 들어 2021년 12월 바이오젠(Biogen Inc.)과 테라파나시아(TheraPanacea)는 신경과학 분야에서 맞춤형 의료를 위한 디지털 헬스 발전에 초점을 맞춘 제휴를 체결했다고 발표했습니다.

맞춤형 의료 시장 보고서 하이라이트

• 이 시장의 전반적인 성장은 유전자 수준에서의 질병에 대한 이해와 전 세계에서 암 및 유전성 질환의 발병률 증가에 따른 새로운 치료제에 대한 수요 증가에 기인하고 있습니다.
• 맞춤형 의료 치료제 부문은 바이오의약품 개발을 위한 약물유전체학의 광범위한 활용으로 인해 예측 기간 중 높은 성장을 보일 것으로 예상됩니다. 또한 유전체 치료제 부문은 전체 유전체 시퀀싱 비용이 크게 감소함에 따라 예측 기간 중 큰 성장을 보일 것으로 예상됩니다.
• 북미는 주요 기업이 존재하고 다양한 질병에 대한 치료법을 찾기 위해 새로운 치료법 개발을 위한 집중적인 연구를 진행하고 있으므로 2023년 시장을 독점하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 맞춤형 의료 시장 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
• 맞춤형 의료 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석

제4장 맞춤형 의료 시장 : 제품 추정·동향 분석

• 제품 시장 점유율, 2023년 및 2030년
• 부문 대시보드
• 제품별 세계 맞춤형 의료 시장 전망
• 2018-2030년 시장 규모와 예측 및 동향 분석

제5장 맞춤형 의료 시장 : 최종 용도 추정·동향 분석

• 메소드 시장 점유율, 2023년과 2030년
• 부문 대시보드
• 최종 용도별 세계의 맞춤형 의료 시장 전망
• 2018-2030년 시장 규모와 예측 및 동향 분석

제6장 맞춤형 의료 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2023년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 스냅숏
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 참여 기업별 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
  • List of key distributors and channel partners
  • Key customers
  • Key company market share analysis, 2023
  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation(Cepheid, Inc.)
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC
  • Biogen
  • Genelex
  • IBM
  • Genentech, Inc.
  • 23andMe, Inc.

KSA

영문 목차

영문목차

Personalized Medicine Market Growth & Trends:

The global personalized medicine market size is expected to reach USD 909.80 billion by 2030, expanding at a CAGR of 8.20% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 7.20% from 2023 to 2030 owing to the increasing incidence of diseases and the rising demand for novel therapeutic drugs. The emerging applications of personalized medicine are consistently enhanced by immense research efforts. For instance, in July 2022, researchers at the UMass Chan Medical School developed a microorganism-based personalized medicine model system to aid the understanding of variation in metabolism to gauge the connection between an individual's genome, diet, microbiota, and associative environmental factors.

Most cancer conditions are usually caused by an underlying genetic discrepancy and can cause fatalities with progression. The cancer condition can be effectively and precisely treated by understanding specific genomic characteristics. For instance, in May 2020, Qiagen launched QIAseq pan-cancer multi-modal panel to enable robust analysis of genomic characteristics of cancer subjects to derive a broad spectrum of applications in precision medicine for the profiling of solid tumors and heme malignancies.

The market is positively driven by advancements in NGS technologies and extensive research on the human genome. There has been an increasing focus on utilizing NGS to derive personalized medicine outcomes that could potentially be used for the treatment of cancer and rare genetic disorders. For instance, Illumina declared that it will present its multiple oncology research abstracts at the European Society of Medical Oncology (ESMO) annual meeting in Paris. Their research enables personalized cancer care using comprehensive genomic profiling of biopsies to match subjects to the potential drugs and immunotherapies.

Telemedicine facilitates virtual or telephonic clinical advice to aid physical convenience. Telemedicine is increasingly trending, especially after the COVID-19 pandemic. Government and research institutes are taking substantial efforts to enhance the applications of personalized telemedicine. For instance, in August 2022, the National Cancer Institute declared a grant of USD 23 million for five years to aid the launch of Telehealth Research Centers of Excellence (TRACE) across the U.S. The program was launched with the support of the White House Cancer Moonshot to seek development and advancements in telehealth delivery for cancer care with a mission to leverage health equity.

Molecular imaging systems and medical devices are playing a primary role in emerging advancements in personalized medicine. They effectively leverage the applications of personalized medicine in the treatment of different types of cancers. For instance, in June 2022, GE Healthcare declared the release of high-end molecular imaging by using gallium-68 radioisotope for the diagnosis and monitoring of prostate cancer so as to leverage access to precision health and theranostics for personalized prostate cancer treatment at an early stage of cancer progression.

The market is in the growth phase due to emerging technological advancements along with consistent industrial efforts such as collaborations and expansions. For instance, in December 2021, Biogen Inc., and TheraPanacea declared that they have signed a collaboration that focuses on advancing digital health for personalized medicine in neuroscience.

Personalized Medicine Market Report Highlights:

• The overall growth of the market is attributed to the rising need for novel therapeutic drugs coupled with leveraged genetic level understanding of diseases and the rising incidence of cancers and genetic disorders across the globe
• The personalized medicine therapeutics segment is anticipated to witness high growth over the forecast period owing to the extensive usage of pharmacogenomics for developing biopharmaceuticals. Further, the genomic medicine therapeutics segment is anticipated to grow substantially during the forecast period owing to significantly lowered costs of whole-genome sequencing
• North America dominated the market in 2023 due to the presence of key players and their intensive research for the development of novel therapies to find out curative solutions for various diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End-use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Personalized Medicine Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in next-generation sequencing technology
    • 3.2.1.2. Expanding portfolio of companion/associated diagnostics
    • 3.2.1.3. Increasing prevalence of cancer & usage of biomarkers for personalized medicine cancer therapy
    • 3.2.1.4. Technological advancements to facilitate R&D for personalized medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Presence of nonvalue-based personalized medicine diagnostics reimbursement policy
    • 3.2.2.2. Lack of proper intellectual property regulations for personalized medical technologies
• 3.3. Personalized Medicine Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Personalized Medicine Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Personalized Medicine Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Personalized Medicine Diagnostics
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.2. Genetic Testing
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.3. DTC Diagnostics
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.4. Esoteric Lab Services
    • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.1.5. Esoteric Lab Tests
    • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Personalized Medicine Therapeutics
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2.2. Pharmaceutical
    • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2.3. Genomic Medicine
    • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2.4. Medical Devices
    • 4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.3. Personalized Medical Care
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3.2. Telemedicine
    • 4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3.3. Health Information Technology
    • 4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.4. Personalized Nutrition & Wellness
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4.2. Retail Nutrition
    • 4.4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4.3. Complementary & Alternative Medicine
    • 4.4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Personalized Medicine Market: End-use Estimates & Trend Analysis

• 5.1. Method Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Personalized Medicine Market by End-use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Hospitals
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Academic & Research Institutes
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.3. Diagnostic Centers
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. Others
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Personalized Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.2. Mexico
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. GE Healthcare
    • 7.3.4.1. Overview
    • 7.3.4.2. Financial Performance
    • 7.3.4.3. Product Benchmarking
    • 7.3.4.4. Strategic Initiatives
  • 7.3.5. Illumina, Inc.
    • 7.3.5.1. Overview
    • 7.3.5.2. Financial Performance
    • 7.3.5.3. Product Benchmarking
    • 7.3.5.4. Strategic Initiatives
  • 7.3.6. ASURAGEN, INC.
    • 7.3.6.1. Overview
    • 7.3.6.2. Financial Performance
    • 7.3.6.3. Product Benchmarking
    • 7.3.6.4. Strategic Initiatives
  • 7.3.7. Abbott
    • 7.3.7.1. Overview
    • 7.3.7.2. Financial Performance
    • 7.3.7.3. Product Benchmarking
    • 7.3.7.4. Strategic Initiatives
  • 7.3.8. Dako A/S
    • 7.3.8.1. Overview
    • 7.3.8.2. Financial Performance
    • 7.3.8.3. Product Benchmarking
    • 7.3.8.4. Strategic Initiatives
  • 7.3.9. Exact Sciences Corporation
    • 7.3.9.1. Overview
    • 7.3.9.2. Financial Performance
    • 7.3.9.3. Product Benchmarking
    • 7.3.9.4. Strategic Initiatives
  • 7.3.10. Danaher Corporation (Cepheid, Inc.)
    • 7.3.10.1. Overview
    • 7.3.10.2. Financial Performance
    • 7.3.10.3. Product Benchmarking
    • 7.3.10.4. Strategic Initiatives
  • 7.3.11. Decode Genetics, Inc.
    • 7.3.11.1. Overview
    • 7.3.11.2. Financial Performance
    • 7.3.11.3. Product Benchmarking
    • 7.3.11.4. Strategic Initiatives
  • 7.3.12. QIAGEN
    • 7.3.12.1. Overview
    • 7.3.12.2. Financial Performance
    • 7.3.12.3. Product Benchmarking
    • 7.3.12.4. Strategic Initiatives
  • 7.3.13. Exagen Inc.
    • 7.3.13.1. Overview
    • 7.3.13.2. Financial Performance
    • 7.3.13.3. Product Benchmarking
    • 7.3.13.4. Strategic Initiatives
  • 7.3.14. Precision Biologics
    • 7.3.14.1. Overview
    • 7.3.14.2. Financial Performance
    • 7.3.14.3. Product Benchmarking
    • 7.3.14.4. Strategic Initiatives
  • 7.3.15. Celera Diagnostics LLC
    • 7.3.15.1. Overview
    • 7.3.15.2. Financial Performance
    • 7.3.15.3. Product Benchmarking
    • 7.3.15.4. Strategic Initiatives
  • 7.3.16. Biogen
    • 7.3.16.1. Overview
    • 7.3.16.2. Financial Performance
    • 7.3.16.3. Product Benchmarking
    • 7.3.16.4. Strategic Initiatives
  • 7.3.17. Genelex
    • 7.3.17.1. Overview
    • 7.3.17.2. Financial Performance
    • 7.3.17.3. Product Benchmarking
    • 7.3.17.4. Strategic Initiatives
  • 7.3.18. IBM
    • 7.3.18.1. Overview
    • 7.3.18.2. Financial Performance
    • 7.3.18.3. Product Benchmarking
    • 7.3.18.4. Strategic Initiatives
  • 7.3.19. Genentech, Inc.
    • 7.3.19.1. Overview
    • 7.3.19.2. Financial Performance
    • 7.3.19.3. Product Benchmarking
    • 7.3.19.4. Strategic Initiatives
  • 7.3.20. 23andMe, Inc.
    • 7.3.20.1. Overview
    • 7.3.20.2. Financial Performance
    • 7.3.20.3. Product Benchmarking
    • 7.3.20.4. Strategic Initiatives

관련자료